Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34 + blood cells to pre-empt relapse in patients with CD34 + myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2012-03, Vol.26 (3), p.381-389
Hauptverfasser:	Platzbecker, U, Wermke, M, Radke, J, Oelschlaegel, U, Seltmann, F, Kiani, A, Klut, I-M, Knoth, H, Röllig, C, Schetelig, J, Mohr, B, Graehlert, X, Ehninger, G, Bornhäuser, M, Thiede, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Azacitidine - adverse effects Azacitidine - therapeutic use Biological and medical sciences Bone marrow Cancer Cancer Research Care and treatment Chimerism Clinical trials Creatinine Critical Care Medicine Female Follow-Up Studies Graft versus host disease Hematologic and hematopoietic diseases Hematology Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Intensive Internal Medicine Leading leading-article Leukemia Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - mortality Leukemia, Myeloid, Acute - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Middle Aged Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - mortality Myelodysplastic Syndromes - therapy Neoplasm, Residual - therapy Oncology Recurrence Relapse Remission (Medicine) Stem cell transplantation Time Factors Transplantation Transplantation, Homologous Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34 + blood cells to pre-empt relapse in patients with CD34 + myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34 + donor chimerism to
ISSN:	0887-6924 1476-5551
DOI:	10.1038/leu.2011.234